Developing new treatments to combat bacterial resistance
Official title: Preclinical Services for Antibacterial Resistance Biopharmaceutical Product Development
Funded at Allucent Government Services (Us) LLC · NIH-10934772 · Data updated 2026-11-12
This study is working on new treatments to help fight stubborn bacterial infections that don't respond to regular antibiotics, using advanced technology to create special medicines that could help patients in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Allucent Government Services (Us) LLC NIH-funded |
| Lab location | 1 site (Cary, United States) |
| Project start | September 8, 2023 |
| Project end | September 7, 2030 |
| Funding year | 2023 |
| Award (this year) | $3,408 |
| NIH project number | 75N93023D00011-0-759302300001-1 |
| Project ID | NIH-10934772 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from infections that are resistant to standard antibiotic treatments.
✕Less likely to help
Patients with infections that are not caused by antibiotic-resistant bacteria may not receive benefit from this research.
What this research studies
This research focuses on the preclinical development of biopharmaceutical products aimed at addressing antibacterial resistance. It utilizes advanced biotechnology processes to create materials such as monoclonal antibodies, recombinant proteins, and small interfering RNA (siRNA) vectors. The program includes comprehensive services like product development planning, assay development, and regulatory support to ensure effective translation of these products into clinical settings. Patients may benefit from innovative therapies that target resistant bacterial infections.
Why it matters
Potential benefit: If successful, this research could lead to new and effective treatments for infections caused by antibiotic-resistant bacteria.
How similar studies have gone: Other research has shown promise in developing biopharmaceuticals targeting bacterial resistance, indicating a potential for success in this area.
Where this research is happening
-
Allucent Government Services (Us) LLC
Cary, United States Active
Related research
Other NIH-funded projects on the same topics.
-
Investigating new treatments for infectious diseases through clinical trials.
This study is looking for people to try out new treatments for infectious diseases that aren't available yet, so if you join, you'll get to help test these therapies while being closely watched for safety and effectiveness.
-
Consulting services for drug metabolism and pharmacokinetics
This study is helping to improve how new drugs are developed by finding and solving problems in the process, which could lead to better treatment options for patients in the future.
-
Consulting on drug metabolism and pharmacokinetics for pain management
This study is all about finding better ways to manage pain by looking at how medications work in the body, and it aims to help patients by improving new pain treatments.
-
Developing new biopharmaceutical products for infectious diseases
This study is working on improving the development of new treatments, like antibodies and RNA therapies, to help fight infectious diseases, so patients can eventually benefit from better options for their health.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.